These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
144 related articles for article (PubMed ID: 25676703)
1. Response letter: Just a matter of luck? Donato MF; Malinverno F; Monico S Liver Int; 2015 Jun; 35(6):1777. PubMed ID: 25676703 [No Abstract] [Full Text] [Related]
2. Optimal duration of pre-liver transplantation anti-hepatitis C virus treatment with direct-acting agent sofosbuvir. Borentain P; Colson P; Darque A; Gérolami R Liver Int; 2015 Jun; 35(6):1776. PubMed ID: 25619265 [No Abstract] [Full Text] [Related]
3. Management of Tacrolimus-Telaprevir Drug-Drug Interaction in a Liver Transplant Patient With Hepatitis C Virus: Practical Considerations. Pape E; Scala-Bertola J; Petitpain N; Jouzeau JY; Charrois-Sciaudeau S; Kemmel V; Barraud H; Gambier N Transplantation; 2015 Sep; 99(9):e163-4. PubMed ID: 26308424 [No Abstract] [Full Text] [Related]
4. Treatment of HCV prior to liver transplantation to prevent HCV recurrence - wise or wasteful? Gallegos-Orozco JF; Charlton MR Liver Int; 2015 Jan; 35(1):9-11. PubMed ID: 25412996 [No Abstract] [Full Text] [Related]
5. PRO view: treat to prevent recurrence of HCV. Everson GT Liver Int; 2015 Jan; 35(1):5-6. PubMed ID: 25729804 [No Abstract] [Full Text] [Related]
6. Sofosbuvir treatment in the pre and post liver transplantation phase: the sooner, the better. Aghemo A; Donato MF Gastroenterology; 2015 Jan; 148(1):13-6. PubMed ID: 25451651 [No Abstract] [Full Text] [Related]
7. Bridging all oral DAA therapy from wait time to post-liver transplant to improve HCV eradication? Donato MF; Monico S; Malinverno F; Aghemo A; Maggioni M; Reggiani P; Colombo M Liver Int; 2015 Jan; 35(1):1-4. PubMed ID: 25074044 [TBL] [Abstract][Full Text] [Related]
8. Sofosbuvir/ledipasvir and ribavirin tolerability and efficacy in pediatric liver transplant recipients. Huysentruyt K; Stephenne X; Varma S; Scheers I; Leclercq G; Smets F; Sokal EM Liver Transpl; 2017 Apr; 23(4):552-553. PubMed ID: 28006874 [No Abstract] [Full Text] [Related]
9. Management of Post-Liver Transplant Recurrence of Hepatitis C. Taylor J; Cox-North P; Landis CS Drugs; 2016 Dec; 76(18):1711-1717. PubMed ID: 27878476 [TBL] [Abstract][Full Text] [Related]
10. [Treatment for hepatitis C before and after liver transplantation]. Ueda Y; Marusawa H Nihon Rinsho; 2015 Dec; 73 Suppl 9():306-10. PubMed ID: 26845950 [No Abstract] [Full Text] [Related]
11. [Recent advances in the treatment of hepatitis C in 2016]. Luo BF; Wei L Zhonghua Gan Zang Bing Za Zhi; 2017 Mar; 25(3):175-180. PubMed ID: 28482403 [TBL] [Abstract][Full Text] [Related]
12. Infections and organ transplantation: new challenges for prevention and treatment of hepatitis C virus. Burra P; De Martin E Transplant Proc; 2011; 43(6):2455-6. PubMed ID: 21839292 [TBL] [Abstract][Full Text] [Related]
13. Management of hepatitis C patients with decompensated liver disease. Hsu CS; Kao JH Expert Rev Gastroenterol Hepatol; 2016 Jun; 10(6):679-88. PubMed ID: 26782619 [TBL] [Abstract][Full Text] [Related]
14. Con: Treating hepatitis C virus With direct-acting antivirals: Fear not the perceived threat of hepatocellular carcinoma. Mehta N; Yao FY Liver Transpl; 2017 Dec; 23(12):1596-1600. PubMed ID: 29024442 [No Abstract] [Full Text] [Related]
15. The importance of IL28B genotype in hepatitis C virus-associated liver transplantation. Lange CM Liver Int; 2013 Feb; 33(2):169-71. PubMed ID: 23295049 [No Abstract] [Full Text] [Related]
16. Sofosbuvir and ribavirin for treatment of compensated recurrent hepatitis C virus infection after liver transplantation. Charlton M; Gane E; Manns MP; Brown RS; Curry MP; Kwo PY; Fontana RJ; Gilroy R; Teperman L; Muir AJ; McHutchison JG; Symonds WT; Brainard D; Kirby B; Dvory-Sobol H; Denning J; Arterburn S; Samuel D; Forns X; Terrault NA Gastroenterology; 2015 Jan; 148(1):108-17. PubMed ID: 25304641 [TBL] [Abstract][Full Text] [Related]
17. [Recurrence of hepatitis B and C after liver transplantation]. Duclos-Vallée JC Rev Prat; 2011 Jan; 61(1):61-4. PubMed ID: 21452545 [No Abstract] [Full Text] [Related]
18. Sofosbuvir and ribavirin prevent recurrence of HCV infection after liver transplantation: an open-label study. Curry MP; Forns X; Chung RT; Terrault NA; Brown R; Fenkel JM; Gordon F; O'Leary J; Kuo A; Schiano T; Everson G; Schiff E; Befeler A; Gane E; Saab S; McHutchison JG; Subramanian GM; Symonds WT; Denning J; McNair L; Arterburn S; Svarovskaia E; Moonka D; Afdhal N Gastroenterology; 2015 Jan; 148(1):100-107.e1. PubMed ID: 25261839 [TBL] [Abstract][Full Text] [Related]
19. Concise review: Interferon-free treatment of hepatitis C virus-associated cirrhosis and liver graft infection. Weiler N; Zeuzem S; Welker MW World J Gastroenterol; 2016 Nov; 22(41):9044-9056. PubMed ID: 27895394 [TBL] [Abstract][Full Text] [Related]
20. Antiviral therapy in liver transplant recipients: is SVR the only endpoint that matters? Kuo A; Terrault NA J Hepatol; 2007 Mar; 46(3):359-61. PubMed ID: 17223220 [No Abstract] [Full Text] [Related] [Next] [New Search]